Published in Virology on May 26, 1997
Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting. J Virol (1998) 1.39
Identification of gp120 regions targeted by a highly potent neutralizing antiserum elicited in a chimpanzee inoculated with a primary human immunodeficiency virus type 1 isolate. J Virol (2000) 1.30
The evolution of poxvirus vaccines. Viruses (2015) 1.02
Poxvirus vectors as HIV/AIDS vaccines in humans. Hum Vaccin Immunother (2012) 1.00
Extensive diversification of human immunodeficiency virus type 1 subtype B strains during dual infection of a chimpanzee that progressed to AIDS. J Virol (1998) 0.96
Nonhuman primate models for HIV/AIDS vaccine development. Curr Protoc Immunol (2013) 0.88
α1Proteinase inhibitor regulates CD4+ lymphocyte levels and is rate limiting in HIV-1 disease. PLoS One (2012) 0.83
Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science (1983) 43.61
Selective tropism of lymphadenopathy associated virus (LAV) for helper-inducer T lymphocytes. Science (1984) 10.38
The complete DNA sequence of vaccinia virus. Virology (1990) 7.76
Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc Natl Acad Sci U S A (1982) 7.04
RNA polymerase activity in purified infectious vaccinia virus. Proc Natl Acad Sci U S A (1967) 5.49
Identification of a new human immunodeficiency virus type 1 distinct from group M and group O. Nat Med (1998) 4.92
HIV-1 reverse transcriptase specifically interacts with the anticodon domain of its cognate primer tRNA. EMBO J (1989) 4.73
Cis elements and trans-acting factors involved in the RNA dimerization of the human immunodeficiency virus HIV-1. J Mol Biol (1990) 4.38
Herpes simplex virus 1 mutant deleted in the alpha 22 gene: growth and gene expression in permissive and restrictive cells and establishment of latency in mice. J Virol (1985) 4.17
ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. J Virol (2002) 4.11
Adaptation of lymphadenopathy associated virus (LAV) to replication in EBV-transformed B lymphoblastoid cell lines. Science (1984) 4.02
The heterosexual human immunodeficiency virus type 1 epidemic in Thailand is caused by an intersubtype (A/E) recombinant of African origin. J Virol (1996) 3.82
Isolation of a T-lymphotropic retrovirus from naturally infected sooty mangabey monkeys (Cercocebus atys). Proc Natl Acad Sci U S A (1986) 3.76
Purification of mRNA guanylyltransferase and mRNA (guanine-7-) methyltransferase from vaccinia virions. J Biol Chem (1975) 3.66
A comprehensive panel of near-full-length clones and reference sequences for non-subtype B isolates of human immunodeficiency virus type 1. J Virol (1998) 3.65
HIV-1 Vpr increases viral expression by manipulation of the cell cycle: a mechanism for selection of Vpr in vivo. Nat Med (1998) 3.61
Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D. Proc Natl Acad Sci U S A (1984) 3.58
Sequence analysis and acute pathogenicity of molecularly cloned SIVSMM-PBj14. Nature (1990) 3.54
Genital mucosal transmission of simian immunodeficiency virus: animal model for heterosexual transmission of human immunodeficiency virus. J Virol (1989) 3.43
NYVAC: a highly attenuated strain of vaccinia virus. Virology (1992) 3.38
Inactivation of lymphadenopathy-associated virus by heat, gamma rays, and ultraviolet light. Lancet (1985) 3.27
Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc Natl Acad Sci U S A (1991) 3.22
Mosaic genome structure of simian immunodeficiency virus from west African green monkeys. EMBO J (1994) 3.19
Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (2000) 3.13
Electrophoresis of thymidine kinase activity synthesized by cells transformed by herpes simplex virus. Virology (1972) 3.05
Molecular genetics of vaccinia virus: demonstration of marker rescue. Proc Natl Acad Sci U S A (1982) 3.01
Effect of immunization with a vaccinia-HIV env recombinant on HIV infection of chimpanzees. Nature (1987) 2.82
Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin. Proc Natl Acad Sci U S A (1983) 2.79
Two major DNA variants present in serially propagated stocks of the WR strain of vaccinia virus. J Virol (1981) 2.74
Persistent infection of chimpanzees with human T-lymphotropic virus type III/lymphadenopathy-associated virus: a potential model for acquired immunodeficiency syndrome. J Virol (1986) 2.65
Vaccinia virus-encoded eIF-2 alpha homolog abrogates the antiviral effect of interferon. Virology (1991) 2.63
Reversal of the interferon-sensitive phenotype of a vaccinia virus lacking E3L by expression of the reovirus S4 gene. J Virol (1995) 2.55
Nucleotide phosphohydrolase in purified vaccinia virus. J Virol (1968) 2.35
Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques. Nat Med (2000) 2.33
Identification and antigenicity of the major envelope glycoprotein of lymphadenopathy-associated virus. Virology (1985) 2.23
Molecular cloning of lymphadenopathy-associated virus. Nature (1985) 2.22
Protein kinase and specific phosphate acceptor proteins associated with vaccinia virus cores. J Virol (1972) 2.22
Diversity of V3 region sequences of human immunodeficiency viruses type 1 from the central African Republic. AIDS Res Hum Retroviruses (1993) 2.22
Programmed cell death and AIDS: significance of T-cell apoptosis in pathogenic and nonpathogenic primate lentiviral infections. Proc Natl Acad Sci U S A (1994) 2.21
Inactivation of lymphadenopathy associated virus by chemical disinfectants. Lancet (1984) 2.19
Universal cellular tropism? Nature (1992) 2.18
Japanese encephalitis virus-vaccinia recombinants produce particulate forms of the structural membrane proteins and induce high levels of protection against lethal JEV infection. Virology (1991) 2.17
Mice immunized with a subviral particle containing the Japanese encephalitis virus prM/M and E proteins are protected from lethal JEV infection. Virology (1992) 2.15
Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine. J Virol (1996) 2.12
Applications of pox virus vectors to vaccination: an update. Proc Natl Acad Sci U S A (1996) 2.10
Modification of the 5'-terminus of mRNA by soluble guanylyl and methyl transferases from vaccinia virus. Proc Natl Acad Sci U S A (1975) 2.10
Immunisation with canarypox virus expressing rabies glycoprotein. Lancet (1992) 2.09
Spectrum of disease in macaque monkeys chronically infected with SIV/SMM. Vet Immunol Immunopathol (1989) 2.09
Vaccinia virus host range genes. Virology (1990) 2.02
HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques. Nat Med (1995) 1.99
Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure. J Virol (1998) 1.98
Effect of virus dose and nonoxynol-9 on the genital transmission of SIV in rhesus macaques. J Med Primatol (1990) 1.97
Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein. Vaccine (2000) 1.97
An analytical model applied to a multicenter pneumococcal enzyme-linked immunosorbent assay study. J Clin Microbiol (2000) 1.97
Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans. Proc Natl Acad Sci U S A (1991) 1.97
Wild Mandrillus sphinx are carriers of two types of lentivirus. J Virol (2001) 1.96
Prevalence of antibodies to lymphadenopathy-associated retrovirus in African patients with AIDS. Science (1984) 1.95
An update on the vaccinia virus genome. Virology (1993) 1.95
The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course? Virology (1994) 1.85
Cloning and expression of foreign genes in vaccinia virus, using a host range selection system. J Virol (1989) 1.84
Nucleotide sequence of HIV1-NDK: a highly cytopathic strain of the human immunodeficiency virus. Gene (1989) 1.83
A molecular clone of HIV-1 tropic and cytopathic for human and chimpanzee lymphocytes. Virology (1993) 1.83
Human alpha- and beta-interferon but not gamma- suppress the in vitro replication of LAV, HTLV-III, and ARV-2. J Interferon Res (1986) 1.83
TAR RNA-binding protein is an inhibitor of the interferon-induced protein kinase PKR. Proc Natl Acad Sci U S A (1994) 1.80
Synthetic peptide strategy for the detection of and discrimination among highly divergent primate lentiviruses. AIDS Res Hum Retroviruses (2001) 1.77
Polyadenylate polymerase from vaccinia virions. Nat New Biol (1973) 1.76
Two nucleic acid-dependent nucleoside triphosphate phosphohydrolases from vaccinia virus. Nucleotide substrate and polynucleotide cofactor specificities. J Biol Chem (1974) 1.76
Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever encephalitis. Virology (1992) 1.76
Antibodies to the core protein of lymphadenopathy-associated virus (LAV) in patients with AIDS. Science (1984) 1.73
The natural history of infection with the lymphadenopathy-associated virus/human T-lymphotropic virus type III. Ann Intern Med (1985) 1.71
Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells. Science (1992) 1.71
Efficacy of nucleoprotein and haemagglutinin antigens expressed in fowlpox virus as vaccine for influenza in chickens. Vaccine (1991) 1.66
A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis (1999) 1.64
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis (1998) 1.64
Recombinant vaccinia virus: immunization against multiple pathogens. Science (1985) 1.60
A distinct African lentivirus from Sykes' monkeys. J Virol (1993) 1.58
A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA. AIDS Res Hum Retroviruses (1995) 1.56
Recombinant fowlpox virus inducing protective immunity in non-avian species. Vaccine (1988) 1.55
Comparison of protective immunity elicited by recombinant vaccinia viruses that synthesize E or NS1 of Japanese encephalitis virus. Virology (1991) 1.55
Canarypox virus-mediated interleukin 12 gene transfer into murine mammary adenocarcinoma induces tumor suppression and long-term antitumoral immunity. Hum Gene Ther (1998) 1.54
Host-range restriction of vaccinia virus E3L-specific deletion mutants. Virus Genes (1996) 1.53
Transcriptional complexity of vaccinia virus in vivo and in vitro. J Virol (1977) 1.53
Effect of canarypox virus (ALVAC)-mediated cytokine expression on murine prostate tumor growth. J Natl Cancer Inst (1997) 1.52
Lymphadenopathy-associated viral antibody in AIDS. Immune correlations and definition of a carrier state. N Engl J Med (1984) 1.51
Nonreplicating viral vectors as potential vaccines: recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins. Virology (1992) 1.48
Two major groups of neutralizing anti-gp120 antibodies exist in HIV-infected individuals. Evidence for epitope diversity around the CD4 attachment site. J Immunol (1992) 1.47